IGF2BP1 and ovarian carcinoma: Whether autoantibodies to IMP1 and p62/IMP2 can be used as the biomarkers for the diagnosis and prediction of ovarian cancer, and the mechanism of immune responses to IMP1 and p62/IMP2 in ovarian cancer remains to be investigated and evaluated.